SRRK Scholar Rock Holding Corporation

+0.03  (+0%)
Previous Close 14.92
Open 14.9
Price To Book 4.02
Market Cap 392,081,750
Shares 26,226,204
Volume 220,523
Short Ratio
Av. Daily Volume 117,460

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initial PK/PD data due YE 2019. Interim efficacy data 1H 2020 with top-line data 4Q 2020. Final Phase 1 data to be presented at Cure SMA Annual Conference being held June 28-July 1, 2019.
Spinal muscular atrophy (SMA

Latest News

  1. Why Carnival, Steelcase, and Scholar Rock Holding Slumped Today
  2. Why Scholar Rock Is Sinking Today
  3. Scholar Rock to Present at the 2019 BMO Prescriptions for Success Healthcare Conference
  4. Scholar Rock Announces Proposed Public Offering of Common Stock
  5. Scholar Rock Announces Positive Final Results from Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers
  6. Scholar Rock to Present at the Jefferies 2019 Global Healthcare Conference
  7. Scholar Rock Reports First Quarter 2019 Financial Results and Highlights Business Progress
  8. Is Scholar Rock Holding Corporation (SRRK) A Good Stock To Buy?
  9. Scholar Rock Announces Initiation of Patient Dosing in Phase 2 Trial of SRK-015 in Spinal Muscular Atrophy
  10. Scholar Rock Appoints Akshay Vaishnaw, M.D., Ph.D. to Its Board of Directors
  11. Scholar Rock Announces Appointment of Lisa Amaya Price as Senior Vice President, Human Resources
  12. Scholar Rock Presents Additional Preclinical Data Demonstrating a Highly Specific Inhibitor of TGFβ1 Activation Can Render Resistant Solid Tumors Vulnerable to PD1 Blockade and Drive Tumor Regression with Combination Therapy
  13. Scholar Rock Reports Full Year 2018 Financial Results and Highlights Business Progress
  14. Scholar Rock to Develop Cancer Immunotherapy Product Candidate, SRK-181, a Selective Inhibitor of TGFβ1 Activation, to Overcome Checkpoint Inhibitor Resistance
  15. Scholar Rock to Participate in Upcoming Investor Conferences
  16. Scholar Rock Announces Positive Interim Results from Phase 1 Trial of SRK-015 in Healthy Volunteers and Updates on Future Development Plans
  17. Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review
  18. Read This Before Selling Scholar Rock Holding Corporation (NASDAQ:SRRK) Shares
  19. Gilead Stock Breaks Out to Channel Resistance
  20. Scholar Rock to Present at the 37th Annual J.P. Morgan Healthcare Conference